RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
MWN-AI** Summary
RxSight, Inc. (NASDAQ: RXST) announced its financial results for the fourth quarter and the fiscal year 2025 on February 25, 2026. The company reported a 12% increase in Light Adjustable Lens (LAL® and LAL+®) unit sales, totaling 109,615 units, with over 300,000 procedures performed since the technology's launch. However, total global sales for 2025 were $134.5 million, which represents a 4% decline from the previous year, primarily due to a significant 48% decrease in Light Delivery Device (LDD™) system sales. Despite the drop in overall revenue, the gross profit margin improved to 76.6% from 70.7% in 2024, attributed to the greater proportion of revenue coming from LAL sales.
The company's operating expenses increased by 11%, reaching $151.2 million, due to investments in commercial initiatives and R&D. RxSight recorded a net loss of $38.9 million for 2025, compared to a loss of $27.5 million in 2024. In Q4, total revenue fell 19% year-over-year to $32.6 million, with LAL revenue down 1% and LDD revenue plummeting 72%. The fourth-quarter net loss increased to $9.2 million, reflecting ongoing challenges.
For 2026, RxSight has set revenue guidance between $120 million to $135 million, citing lower expected LDD placements. The anticipated gross margin is projected at 70% to 72%, due to increased manufacturing costs. The company remains committed to expanding its international presence, including a recent regulatory approval in Australia.
CEO Ron Kurtz expressed optimism about the company's strategic initiatives in boosting LAL adoption and solidifying its market position in ophthalmic devices.
MWN-AI** Analysis
RxSight, Inc. (NASDAQ: RXST) recently reported its fiscal 2025 financial results, revealing key developments and challenges, particularly in Light Delivery Device (LDD) sales, which plummeted by 48%. Conversely, Light Adjustable Lens (LAL) sales experienced a commendable 12% growth, reflecting strong demand for customizable vision correction post-cataract surgery. Although RxSight achieved a significant milestone with over 300,000 LAL procedures performed since the product's launch, the 2025 total sales of $134.5 million represented a 4% decline compared to the previous year. This trend raises concerns about the sustainability of growth amidst rising competition in the ophthalmic market.
The company’s guidance for 2026 indicates further challenges, projecting revenue of $120 million to $135 million. This estimation accounts for a reduction in LDD placements, suggesting that RxSight needs to enhance its market penetration strategies. The forecasted gross margin of 70-72% signals elevated production costs, primarily affecting LDD pricing dynamics.
Investors should note RxSight’s operating expenses are on an upward trajectory, having increased 11% in 2025, which could pressure profitability unless sales growth accelerates. Despite experiencing a net loss of $38.9 million, stakeholders might be encouraged by the company’s healthy cash reserve of $228 million, enabling it to invest in innovation and market expansion.
With RxSight anticipates continued adoption of LAL technology, effective commercialization efforts are crucial. Investors should closely monitor the company's Q1 2026 performance, particularly how initial indicators reflect new strategies. Caution is warranted until RxSight demonstrates sustained growth, particularly in LDD sales, an essential driver of its business model. Diversifying offerings and expanding into new markets, such as the recent Australian approval, will be pivotal for long-term success. Adjusting one’s portfolio may be prudent as RxSight navigates a challenging landscape in the ophthalmic sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025.
Strategic Highlights and Recent Developments
- 2025 Light Adjustable Lens (LAL® and LAL+®) unit sales increased 12% to 109,615
- Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practice
- Light Delivery Devices (LDD™) installed base expanded to 1,134, providing a strong foundation for future procedure growth
- RxSight’s FDA Post-approval study results, demonstrating statistically superior outcomes for LAL eyes compared to historical results from contemporary toric IOLs, were accepted for publication in the Journal of Cataract & Refractive Surgery
- Regulatory approval received in Australia, expanding the company’s addressable international opportunity
“Based on our fourth quarter results, we believe that the commercial initiatives implemented in the second half of 2025 are showing early signs of progress,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “While there is still more work ahead, full year LAL growth reflected strong adoption as physicians and patients recognize the value of the company’s differentiated therapy. Our team remains committed to driving the disciplined execution that supports doctors as they deliver the benefits of high-quality customized vision to their patients.”
Fiscal Year 2025 Financial Results
Full-year 2025 global sales of $134.5 million decreased 4% versus the prior year. LAL revenue growth of 12% was offset by a 48% decrease in LDD system sales compared to 2024.
2025 gross profit was $103.0 million, or 76.6% of revenue compared to gross profit of $98.9 million, or 70.7% of revenue in 2024. The increase in gross margin was primarily due to a greater percentage of revenue from LAL sales.
Operating expenses for 2025 were $151.2 million, an 11% increase compared to $135.8 million in 2024. The increase was driven primarily by strategic investments to support our expanding commercial and operational footprint, in addition to research and development and marketing activities. The company is building international infrastructure and maintains regulatory approvals for the RxSight system in North America, Europe, Singapore, South Korea and, most recently, Australia.
In 2025, net loss was $(38.9) million, or $(0.95) per share on a basic and diluted basis compared to a net loss of $(27.5) million, or $(0.71) per share on a basic and diluted basis in 2024. Adjusted net loss was $(7.3) million, or $(0.18) per share on a basic and diluted basis, in 2025, compared to an adjusted net loss of $(2.8) million, or $(0.07) per share on a basic and diluted basis in 2024.
As of December 31, 2025, cash, cash equivalents and short-term investments totaled $228.1 million.
Fourth Quarter Financial Results
In the fourth quarter of 2025, total revenue was $32.6 million, a decrease of 19% compared to $40.2 million in the fourth quarter of 2024, largely reflecting lower LDD revenue compared to record LDD placements in the prior year period. For the quarter, LAL revenue decreased 1% year over year, while LDD revenue decreased 72%. Sequential LAL procedure growth reflects steady activity across the installed base, supported in part by recent commercial initiatives and typical seasonal trends.
Fourth quarter gross profit was $25.3 million or 77.5% of revenue, a decrease of $3.5 million compared to gross profit of $28.8 million or 71.6% of revenue for the year-ago period. The increase in gross profit as percent of revenue was primarily driven by the favorable shift in product mix toward LAL sales.
Total operating expenses were $36.6 million, a 2% decrease from $37.4 million in the year-ago period. The decrease was driven by lower personnel costs, partially offset by continued investments to support LAL sales and advance the company’s research and development pipeline.
In the fourth quarter of 2025, the company reported a net loss of $(9.2) million, or $(0.22) per basic and diluted share, compared to a net loss of $(5.9) million, or $(0.15) per basic and diluted share in the fourth quarter of 2024. Adjusted net loss in the fourth quarter of 2025 was $(1.3) million, or $(0.03) per basic and diluted share, compared to an adjusted net gain of $1.3 million, or $0.03 per basic and diluted share in the fourth quarter of 2024.
Unit Sales Summary
| Product | 2025 Units Sold | YoY Change vs. 2024 | Q4 2025 Units Sold | YoY Change vs. Q4 2024 | QoQ Change vs. Q3 2025 |
| Light Adjustable Lenses | 109,615 | +12% | 28,611 | (2%) | +10% |
| Light Delivery Devices | 163 | (47%) | 25 | (70%) | 0% |
2026 Guidance
The company provided its full year 2026 financial guidance as follows:
- Revenue of $120.0 to $135.0 million, reflecting lower year-over-year LDD placements;
- Gross margin of 70% to 72%, driven by higher per-unit manufacturing costs associated with lower LDD production volumes;
- Operating expenses of $150.0 million to $160.0 million; and
- Non-cash stock-based compensation expense of $30.0 million to $32.0 million.
Conference Call
On Wednesday, February 25, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its fourth quarter and full year 2025 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 3406720. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-Looking Statements
This press release contains forward-looking statements, including: statements regarding the company’s expectations that commercial initiatives implemented in the second half of 2025 are showing early signs of progress; statements relating to 2025 LAL growth and adoption trends in the United States; and statements concerning the company’s commitment to disciplined execution in support of physicians delivering customized vision solutions to their patients. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part I, Item 1A (Risk Factors) in the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
| RxSight, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (In thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Sales | $ | 32,607 | $ | 40,214 | $ | 134,479 | $ | 139,927 | |||||||
| Cost of sales | 7,344 | 11,426 | 31,470 | 40,984 | |||||||||||
| Gross profit | 25,263 | 28,788 | 103,009 | 98,943 | |||||||||||
| Operating expenses: | |||||||||||||||
| Selling, general and administrative | 27,694 | 28,209 | 112,651 | 101,434 | |||||||||||
| Research and development | 8,905 | 9,208 | 38,549 | 34,367 | |||||||||||
| Total operating expenses | 36,599 | 37,417 | 151,200 | 135,801 | |||||||||||
| Loss from operations | (11,336 | ) | (8,629 | ) | (48,191 | ) | (36,858 | ) | |||||||
| Other income (expense), net: | |||||||||||||||
| Interest expense | (4 | ) | (5 | ) | (19 | ) | (21 | ) | |||||||
| Interest and other income | 2,195 | 2,708 | 9,332 | 9,474 | |||||||||||
| Loss before income taxes | (9,145 | ) | (5,926 | ) | (38,878 | ) | (27,405 | ) | |||||||
| Income tax expense | 6 | 12 | 66 | 50 | |||||||||||
| Net loss | $ | (9,150 | ) | $ | (5,938 | ) | $ | (38,944 | ) | $ | (27,455 | ) | |||
| Other comprehensive (loss) income | |||||||||||||||
| Unrealized (loss) gain on short-term investments | (13 | ) | (344 | ) | (136 | ) | 180 | ||||||||
| Foreign currency translation gain (loss) | 5 | (12 | ) | 23 | (9 | ) | |||||||||
| Total other comprehensive (loss) income | (8 | ) | (356 | ) | (113 | ) | 171 | ||||||||
| Comprehensive loss | $ | (9,159 | ) | $ | (6,294 | ) | $ | (39,057 | ) | $ | (27,284 | ) | |||
| Net loss per share: | |||||||||||||||
| Basic and diluted | $ | (0.22 | ) | $ | (0.15 | ) | $ | (0.95 | ) | $ | (0.71 | ) | |||
| Weighted-average shares used in computing net loss per share: | |||||||||||||||
| Attributable to common stock, basic and diluted | 41,175,725 | 40,356,756 | 40,850,739 | 38,867,726 | |||||||||||
| RxSight, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts) | |||||||
| December 31, | December 31, | ||||||
| 2025 | 2024 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 19,949 | $ | 16,706 | |||
| Short-term investments | 208,179 | 220,517 | |||||
| Accounts receivable | 23,383 | 30,050 | |||||
| Inventories, net | 31,559 | 22,009 | |||||
| Prepaid and other current assets | 4,389 | 4,541 | |||||
| Total current assets | 287,459 | 293,823 | |||||
| Property and equipment, net | 13,056 | 12,413 | |||||
| Operating leases right-of-use assets | 9,959 | 11,217 | |||||
| Restricted cash | 750 | 750 | |||||
| Other assets | 590 | 360 | |||||
| Total assets | $ | 311,814 | $ | 318,563 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 5,296 | $ | 4,544 | |||
| Accrued expenses and other current liabilities | 19,795 | 20,358 | |||||
| Lease liabilities | 1,162 | 974 | |||||
| Total current liabilities | 26,253 | 25,876 | |||||
| Long-term lease liabilities | 9,878 | 11,322 | |||||
| Other long-term liabilities | — | 127 | |||||
| Total liabilities | 36,131 | 37,325 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity: | |||||||
| Common stock, $0.001 par value, 900,000,000 shares authorized, 41,242,005 shares issued and outstanding as of December 31, 2025 and 40,428,220 shares issued and outstanding as of December 31, 2024 | 41 | 40 | |||||
| Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding | — | — | |||||
| Additional paid-in capital | 936,628 | 903,127 | |||||
| Accumulated other comprehensive loss | 53 | 166 | |||||
| Accumulated deficit | (661,039 | ) | (622,095 | ) | |||
| Total stockholders' equity | 275,683 | 281,238 | |||||
| Total liabilities and stockholders' equity | $ | 311,814 | $ | 318,563 |
Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net earnings (loss), and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because this expense is non-cash in nature and we believe excluding this item provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.
We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share
Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for stock-based compensation. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.
Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:
| Three months ended December 31, | Year ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Common Stock | ||||||||||||||||
| Numerator: | ||||||||||||||||
| Net loss available to stockholders, basic and diluted | $ | (9,151 | ) | $ | (5,938 | ) | $ | (38,944 | ) | $ | (27,455 | ) | ||||
| Add: | ||||||||||||||||
| Stock-based compensation | 7,818 | 7,282 | 31,612 | 24,635 | ||||||||||||
| Adjusted net (loss) income available to common stockholders, basic and diluted: | $ | (1,333 | ) | $ | 1,344 | $ | (7,332 | ) | $ | (2,820 | ) | |||||
| Denominator: | ||||||||||||||||
| Weighted-average shares outstanding, basic | 41,175,725 | 40,356,756 | 40,850,739 | 38,867,726 | ||||||||||||
| Weighted-average shares outstanding, diluted | 41,175,725 | 45,622,429 | 40,850,739 | 38,867,726 | ||||||||||||
| Adjusted net earnings (loss) per share, basic | $ | (0.03 | ) | $ | 0.03 | $ | (0.18 | ) | $ | (0.07 | ) | |||||
| Adjusted net earnings (loss) per share, diluted | $ | (0.03 | ) | $ | 0.03 | $ | (0.18 | ) | $ | (0.07 | ) |
FAQ**
How does RxSight Inc. RXST plan to address the significant decrease in Light Delivery Device (LDD) sales in 2025, which dropped 48% compared to the previous year?
Given the recent regulatory approval in Australia, what strategies is RxSight Inc. RXST implementing to expand its international market presence in 2026?
RxSight Inc. RXST has forecasted revenues between $120 million to $1million for 2026; what specific factors do you attribute to the anticipated decline in overall sales compared to 2025?
With the reported net loss of $(38.9) million in 2025, what measures is RxSight Inc. RXST taking to improve financial performance and reduce losses in the coming fiscal year?
**MWN-AI FAQ is based on asking OpenAI questions about RxSight Inc. (NASDAQ: RXST).
NASDAQ: RXST
RXST Trading
4.25% G/L:
$7.725 Last:
111,089 Volume:
$7.64 Open:
